Abstract: Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-? inhibiting NK cells to disable the inhibition of immune system, and Th1 cytokine activates NK cells in host to enhance the ability fighting against tumor cells. By means of the complex immuno-gene medical composition, removal of tumor cells is expectable.

Abstract: A chimeric protein expressed from a transgene tranduced into a mammalian tumor cell and method of using the chimeric protein for cancer treatment. The chimeric protein comprises an effector and an anchor, which are linked by a spacer. The chimeric protein, when expressed and exposed on the tumor cell surface in vivo can activate T cells, which further lead to lysis of the tumor cells. The anti-tumor effects can be enhanced by co-expression of certain co-stimulators, such as CD80 or CD86.

Abstract: The present invention herein relates to a bioactive substance with mammalian B lymphocyte toxicity secreted by canine transmissible venereal tumor (CTVT) and its process. CTVT is the only mammalian tumor in nature that is transmitted through viable tumor cells. Transmission of CTVT between dogs is akin to an allograft. The isolation of bioactive substance secreted by CTVT includes the following steps: (1) store CTVT excised from canine skin in Hank's balanced salt solution (HBSS); (2) physically extract CTVT, tumor infiltrating lymphocytes and peripheral blood lymphocytes; (3) place CTVT in culture medium and physically obtain suspension fluid with B lymphocyte toxicity; (4) drive said suspension solution through protein filters with different pore sizes to obtain bioactive substance.